-

BostonGene Named One of Massachusetts Best Genetics and Bioinformatics Startups

 Criteria for Recognition Includes Exceptional Performance in Innovation, Growth, Management or Societal Impact

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, announced today that BestStartup.us had named BostonGene a top Massachusetts startup in two categories, “Genetics” and “Bioinformatics."

BestStartup.us evaluated companies on various criteria, including innovation, growth, management, or societal impact. BestStartup.us aims to highlight companies promoting innovative products and breakthrough ideas across the United States.

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to advance the standard of care, accelerate research, and improve economics. The BostonGene Tumor Portrait Test™, based on integrated genomic and transcriptomic analysis, propels precision medicine into daily clinical practice and supports physicians in actualizing personalized therapy for cancer patients. BostonGene collaborates with many of the leading cancer centers across the United States for research and clinical adoption.

“We are honored to receive this recognition from BestStartup.us,” said Erin O’Reilly, Senior Director, Marketing at BostonGene. “The acknowledgment validates our ongoing commitment to identify novel and personalized treatment options through next-generation multi-platform analytics, further advancing and optimizing outcomes for each cancer patient.”

About BostonGene Corporation

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

Media:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

Industry:

BostonGene Corporation

Release Versions
English

Contacts

Media:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

More News From BostonGene Corporation

BostonGene RNA Transcriptome Profiling Reveals New ADC Targets in Advanced Solid Tumors

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study in collaboration with The University of Texas MD Anderson Cancer Center, evaluating the clinical utility of comprehensive transcriptome testing in patients with advanced solid tumors. Findings from the prospective study in Cancer Discovery, “Clinical Utility of Comprehensive Transcriptome Testing in Advanced Solid Tumors”, demonstrated th...

BostonGene Demonstrates Disease Modeling Platform at JSMO 2026, Advancing AI-Driven Drug Development and Precision Oncology

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced its participation at the 23rd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2026) from March 26–28, 2026, in Yokohama, Japan. The premier oncology conference brings together over 7,000 global experts to discuss the advancements in cancer research and clinical practice. The conference focuses on bridging the gap between cutting-edge evidence an...

BostonGene Advances AI-Driven Disease Modeling in Oncology in Collaboration with Leading Experts in Cancer Genomics at USCAP 115th Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced an oral presentation at the United States and Canadian Academy of Pathology (USCAP) 115th Annual Meeting. The session highlights new clinical data generated in collaboration with leading academic investigators, including Weill Cornell Medicine. The event, held from March 21-26 at the Henry B. González Convention Center in San Antonio, TX, is the world's premier...
Back to Newsroom